## Andrea Gallina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4569565/publications.pdf

Version: 2024-02-01

424 papers 11,133 citations

24978 57 h-index 94 g-index

431 all docs

431 docs citations

431 times ranked

8232 citing authors

#	Article	IF	CITATIONS
1	Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. European Urology, 2012, 61, 480-487.	0.9	594
2	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	0.8	474
3	Complications and Other Surgical Outcomes Associated with Extended Pelvic Lymphadenectomy in Men with Localized Prostate Cancer. European Urology, 2006, 50, 1006-1013.	0.9	341
4	Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy. European Urology, 2009, 55, 261-270.	0.9	263
5	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	0.9	228
6	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. European Urology, 2015, 67, 299-309.	0.9	211
7	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	0.9	209
8	A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 3576-3581.	0.8	205
9	Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis. European Urology, 2011, 59, 832-840.	0.9	180
10	Câ€reactive protein is an informative predictor of renal cell carcinomaâ€specific mortality. Cancer, 2007, 110, 1241-1247.	2.0	165
11	Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy. European Urology, 2009, 55, 1003-1011.	0.9	164
12	Impact on Sexual Function of Holmium Laser Enucleation Versus Transurethral Resection of the Prostate: Results of a Prospective, 2-Center, Randomized Trial. Journal of Urology, 2006, 175, 1817-1821.	0.2	162
13	Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU International, 2006, 98, 788-793.	1.3	162
14	Critical Assessment of Ideal Nodal Yield at Pelvic Lymphadenectomy to Accurately Diagnose Prostate Cancer Nodal Metastasis in Patients Undergoing Radical Retropubic Prostatectomy. Urology, 2007, 69, 147-151.	0.5	156
15	Extended 21-Sample Needle Biopsy Protocol for Diagnosis of Prostate Cancer in 1000 Consecutive Patients. European Urology, 2007, 52, 430-435.	0.9	148
16	Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey. European Urology, 2009, 56, 1025-1032.	0.9	141
17	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 2008, 53, 794-802.	0.9	137
18	When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. European Urology, 2010, 57, 551-558.	0.9	137

#	Article	IF	Citations
19	Improving the Preservation of the Urethral Sphincter and Neurovascular Bundles During Open Radical Retropubic Prostatectomy. European Urology, 2005, 48, 938-945.	0.9	135
20	Comparison of stage migration patterns between Europe and the USA: an analysis of $11\hat{A}350$ men treated with radical prostatectomy for prostate cancer. BJU International, 2008, $101$ , $1513-1518$ .	1.3	134
21	Clinicians are poor raters of lifeâ€expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU International, 2007, 100, 1254-1258.	1.3	129
22	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	0.9	128
23	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. European Urology, 2012, 61, 1132-1138.	0.9	120
24	Development and External Validation of an Extended 10-Core Biopsy Nomogram. European Urology, 2007, 52, 436-445.	0.9	114
25	Nerveâ€sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. BJU International, 2013, 111, 717-722.	1.3	108
26	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2013, 63, 998-1008.	0.9	107
27	Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: An inpatient cost analysis. Urology, 2006, 68, 302-306.	0.5	104
28	Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer. Urology, 2009, 73, 1087-1091.	0.5	102
29	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. Journal of Sexual Medicine, 2010, 7, 2521-2531.	0.3	102
30	Benign Prostatic Hyperplasia and Its Aetiologies. European Urology Supplements, 2009, 8, 865-871.	0.1	96
31	Biopsy Schemes with the Fewest Cores for Detecting 95% of the Prostate Cancers Detected by a 24-Core Biopsy. European Urology, 2010, 57, 1-8.	0.9	94
32	Prostate Cancer Nomograms: An Update. European Urology, 2006, 50, 914-926.	0.9	89
33	Acceptance of and Discontinuation Rate from Erectile Dysfunction Oral Treatment in Patients following Bilateral Nerve-Sparing Radical Prostatectomy. European Urology, 2008, 53, 564-570.	0.9	88
34	Trans-rectal Versus Trans-Perineal Saturation Rebiopsy of the Prostate: Is There a Difference in Cancer Detection Rate?. Urology, 2011, 77, 921-925.	0.5	87
35	Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Annals of Oncology, 2013, 24, 1459-1466.	0.6	87
36	Percentage of Positive Biopsy Cores Can Improve the Ability to Predict Lymph Node Invasion in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. European Urology, 2007, 51, 1573-1581.	0.9	84

#	Article	IF	Citations
37	Prostate volume and adverse prostate cancer features: Fact not artifact. European Journal of Cancer, 2007, 43, 2669-2677.	1.3	82
38	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. European Urology, 2014, 65, 546-551.	0.9	81
39	Initial Biopsy Outcome Prediction—Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. European Urology, 2007, 51, 1236-1243.	0.9	79
40	Lymphatic spread of nodal metastases in highâ€risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. Prostate, 2012, 72, 186-192.	1.2	79
41	Apparent Diffusion Coefficient Value and Ratio as Noninvasive Potential Biomarkers to Predict Prostate Cancer Grading: Comparison With Prostate Biopsy and Radical Prostatectomy Specimen. American Journal of Roentgenology, 2015, 204, 550-557.	1.0	78
42	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	1.3	77
43	CURRENTLY USED CRITERIA FOR ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER. AN ANALYSIS OF PATHOLOGICAL FEATURES. Journal of Urology, 2008, 179, 152-152.	0.2	76
44	Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. European Urology, 2012, 62, 42-52.	0.9	75
45	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	0.9	75
46	Baseline Potency in Candidates for Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. European Urology, 2006, 50, 360-365.	0.9	71
47	Extent of lymph node dissection at nephrectomy affects cancerâ€specific survival and metastatic progression in specific subâ€categories of patients with renal cell carcinoma ( <scp>RCC</scp> ). BJU International, 2014, 114, 210-215.	1.3	69
48	Long-term Biochemical Recurrence Rates After Robot-assisted Radical Prostatectomy: Analysis of a Single-center Series of Patients With a Minimum Follow-up of 5 Years. Urology, 2012, 79, 133-138.	0.5	68
49	The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. Journal of Urology, 2019, 202, 108-113.	0.2	67
50	A Nomogram for Staging of Exclusive Nonobturator Lymph Node Metastases in Men with Localized Prostate Cancer. European Urology, 2007, 51, 112-120.	0.9	66
51	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 335-341.	0.8	66
52	Preserved Postoperative Penile Size Correlates Well with Maintained Erectile Function after Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. European Urology, 2007, 52, 702-707.	0.9	65
53	Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. BJU International, 2006, 98, 1204-1209.	1.3	62
54	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 3648-3657.	3.2	62

#	Article	IF	CITATIONS
55	Development and Split-Sample Validation of a Nomogram Predicting the Probability of Seminal Vesicle Invasion at Radical Prostatectomy. European Urology, 2007, 52, 98-105.	0.9	61
56	Radical Prostatectomy for Incidental (Stage T1a–T1b) Prostate Cancer: Analysis of Predictors for Residual Disease and Biochemical Recurrence. European Urology, 2008, 54, 118-125.	0.9	61
57	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. European Urology, 2008, 54, 794-804.	0.9	61
58	Menstrual Cycle-Related Changes in Circulating Androgens in Healthy Women With Self-Reported Normal Sexual Function. Journal of Sexual Medicine, 2008, 5, 854-863.	0.3	59
59	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 2011, 107, 1095-1101.	1.3	58
60	The human cytomegalovirus UL45 gene product is a late, virion-associated protein and influences virus growth at low multiplicities of infection. Journal of General Virology, 2003, 84, 3359-3370.	1.3	55
61	PATIENTS WITH ORGAN CONFINED PROSTATE CANCER AND POSTITIVE SURGICAL MARGINS HAVE SIMILAR RECURRENCE RATES COMPARED TO PATIENTS WITH EXTRA-CAPSULAR EXTENSION AND NEGATIVE SURGICAL MARGINS. A PLEA FOR STAGE RE-CLASSIFICATION. Journal of Urology, 2009, 181, 290-290.	0.2	55
62	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. European Urology, 2020, 77, 576-580.	0.9	55
63	Predicting the risk of bone metastasis in prostate cancer. Cancer Treatment Reviews, 2014, 40, 3-11.	3.4	53
64	Differences in trends in the use of robotâ€assisted and open radical cystectomy and changes over time in periâ€operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. BJU International, 2019, 124, 656-664.	1.3	53
65	Topical Prilocaine-Lidocaine Cream Combined with Peripheral Nerve Block Improves Pain Control in Prostatic Biopsy: Results from a Prospective Randomized Trial. European Urology, 2008, 53, 967-975.	0.9	49
66	Testing the most stringent criteria for selection of candidates for active surveillance in patients with lowâ€risk prostate cancer. BJU International, 2010, 105, 1548-1552.	1.3	49
67	Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. European Urology, 2017, 72, 432-438.	0.9	49
68	Preoperative hypogonadism is not an independent predictor of highâ€risk disease in patients undergoing radical prostatectomy. Cancer, 2011, 117, 3953-3962.	2.0	47
69	Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Current Opinion in Urology, 2009, 19, 38-43.	0.9	45
70	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nature Reviews Urology, 2005, 2, 239-247.	1.4	44
71	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. International Journal of Cancer, 2007, 121, 791-795.	2.3	44
72	Mortality at 120 days after prostatic biopsy: A populationâ€based study of 22,175 men. International Journal of Cancer, 2008, 123, 647-652.	2.3	44

#	Article	IF	CITATIONS
73	Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention. Korean Journal of Urology, 2011, 52, 507.	1.2	44
74	Use of Preoperative Plasma Endoglin for Prediction of Lymph Node Metastasis in Patients with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2008, 14, 1418-1422.	3.2	43
75	Acceptance of and Discontinuation Rate from Paroxetine Treatment in Patients with Lifelong Premature Ejaculation. Journal of Sexual Medicine, 2009, 6, 2868-2877.	0.3	43
76	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during followâ€up. BJU International, 2013, 112, E59-66.	1.3	42
77	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naÃ <sup>-</sup> ve Urothelial Bladder Cancer Patients. European Urology Oncology, 2020, 3, 784-788.	2.6	41
78	THE EFFECT OF ANDROGEN DEPRIVATION THERAPY ON THE RATE OF SUBSEQUENT NON-CANCER MORBIDITIES. Journal of Urology, 2008, 179, 186-186.	0.2	40
79	Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?. Prostate Cancer and Prostatic Diseases, 2011, 14, 74-78.	2.0	38
80	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Sexual Medicine, 2011, 8, 1210-1217.	0.3	38
81	Management of erectile dysfunction after radical prostatectomy in 2007. World Journal of Urology, 2007, 25, 143-148.	1.2	37
82	Remembered International Index of Erectile Function Domain Scores Are Not Accurate in Assessing Preoperative Potency in Candidates for Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. Journal of Sexual Medicine, 2008, 5, 677-683.	0.3	36
83	Systematic Assessment of the Ability of the Number and Percentage of Positive Biopsy Cores to Predict Pathologic Stage and Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 52, 733-745.	0.9	35
84	Nerve-Sparing Radical Retropubic Prostatectomy in Patients Previously Submitted to Holmium Laser Enucleation of the Prostate for Bladder Outlet Obstruction Due to Benign Prostatic Enlargement. European Urology, 2008, 53, 1180-1185.	0.9	35
85	Circulating estradiol, but not testosterone, is a significant predictor of highâ€grade prostate cancer in patients undergoing radical prostatectomy. Cancer, 2011, 117, 5029-5038.	2.0	35
86	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.2	35
87	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 608-617.	0.3	35
88	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasoundâ€guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU International, 2012, 110, E64-8.	1.3	34
89	Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World Journal of Urology, 2015, 33, 1389-1395.	1.2	34
90	A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2015, 68, 750-753.	0.9	34

#	Article	IF	CITATIONS
91	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU International, 2007, 100, 528-532.	1.3	33
92	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. BJU International, 2013, 111, 1222-1230.	1.3	33
93	External Validation of the European Association of Urology Recommendations for Pelvic Lymph Node Dissection in Patients Treated with Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2014, 28, 416-423.	1.1	33
94	The Optimal Rebiopsy Prostatic Scheme Depends on Patient Clinical Characteristics: Results of a Recursive Partitioning Analysis Based on a 24-Core Systematic Scheme. European Urology, 2011, 60, 834-841.	0.9	32
95	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU International, 2011, 108, 366-371.	1.3	31
96	Erectile Function Outcome after Bilateral Nerve Sparing Radical Prostatectomy: Which Patients May Be Left Untreated?. Journal of Sexual Medicine, 2012, 9, 903-908.	0.3	31
97	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World Journal of Urology, 2013, 31, 275-280.	1.2	31
98	Random biopsy: when, how many and where to take the cores?. World Journal of Urology, 2014, 32, 859-869.	1.2	30
99	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 48-53.	3.0	30
100	Penile implants in the era of oral drug treatment for erectile dysfunction. BJU International, 2004, 94, 745-751.	1.3	29
101	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer, 2007, 43, 1180-1187.	1.3	29
102	Accuracy of Life Tables in Predicting Overall Survival in Candidates for Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 88-94.	0.4	29
103	Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. International Journal of Radiation Oncology Biology Physics, 2012, 83, 624-629.	0.4	29
104	Prostate Cancer-Specific Survival in Men Treated with Hormonal Therapy after Failure of Radical Prostatectomy. European Urology, 2007, 52, 446-454.	0.9	28
105	Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 29.e21-29.e28.	0.8	28
106	Predictive models before and after radical prostatectomy. Prostate, 2010, 70, 1371-1378.	1.2	27
107	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. Clinical Genitourinary Cancer, 2017, 15, e603-e607.	0.9	27
108	Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2007, 13, 5377-5384.	3.2	26

#	Article	IF	CITATIONS
109	Influence of obesity on tumour volume in patients with prostate cancer. BJU International, 2012, 109, 678-684.	1.3	26
110	Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 291.e9-291.e17.	0.8	26
111	Balancing continence function and oncological outcomes during robotâ€assisted radical prostatectomy (RARP). BJU International, 2011, 108, 999-1006.	1.3	25
112	Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. Urologia Internationalis, 2012, 89, 126-135.	0.6	25
113	Ageâ€adjusted validation of the most stringent criteria for active surveillance in lowâ€risk prostate cancer patients. Cancer, 2012, 118, 973-980.	2.0	25
114	Radical prostatectomy represents an effective treatment in patients with specimenâ€confined high pathological <scp>G</scp> leason score prostate cancer. BJU International, 2013, 111, 723-730.	1.3	25
115	A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. BJU International, 2008, 101, 556-560.	1.3	24
116	Sperm banking is of key importance in patients with prostate cancer. Fertility and Sterility, 2013, 100, 367-372.e1.	0.5	24
117	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. European Urology, 2021, 80, 319-322.	0.9	24
118	Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 51, 949-955.	0.9	23
119	National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate Cancer. Journal of Urology, 2012, 188, 423-428.	0.2	23
120	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399.	1.0	23
121	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study. Cancers, 2019, 11, 700.	1.7	23
122	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. European Urology Oncology, 2021, 4, 1001-1005.	2.6	23
123	How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. Journal of Endourology, 2014, 28, 792-800.	1.1	22
124	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 76.e1-76.e9.	0.8	22
125	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. Clinical Genitourinary Cancer, 2020, 18, e543-e556.	0.9	22
126	External Validation of a Nomogram for Prediction of Side-Specific Extracapsular Extension at Robotic Radical Prostatectomy. Journal of Endourology, 2007, 21, 1345-1352.	1.1	21

#	Article	IF	CITATIONS
127	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerveâ€sparing radical prostatectomy. International Journal of Urology, 2013, 20, 413-419.	0.5	21
128	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e1-57.e7.	0.8	21
129	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU International, 2011, 108, 1769-1775.	1.3	20
130	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e7-256.e13.	0.8	20
131	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	2.6	20
132	Contemporary conditional cancerâ€specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. Journal of Surgical Oncology, 2020, 121, 1154-1161.	0.8	20
133	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU International, 2007, 100, 37-41.	1.3	19
134	Prostate-Specific Antigen Improves the Ability of Clinical Stage and Biopsy Gleason Sum to Predict the Pathologic Stage at Radical Prostatectomy in the New Millennium. European Urology, 2007, 52, 1067-1075.	0.9	19
135	Role of Urinary Cathepsin B and L in the Detection of Bladder Urothelial Cell Carcinoma. Journal of Urology, 2008, 179, 478-484.	0.2	19
136	When should we expect no residual tumor (pT0) once we submit incidental T1aâ€b prostate cancers to radical prostatectomy?. International Journal of Urology, 2011, 18, 148-153.	0.5	19
137	The Number of Cores Taken in Patients Diagnosed with a Single Microfocus at Initial Biopsy is a Major Predictor of Insignificant Prostate Cancer. Journal of Urology, 2013, 189, 854-859.	0.2	19
138	Does Educational Status Affect a Patient's Behavior Toward Erectile Dysfunction?. Journal of Sexual Medicine, 2008, 5, 1941-1948.	0.3	18
139	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. International Journal of Urology, 2009, 16, 526-529.	0.5	18
140	Sex Hormone-binding Globulin: A Novel Marker for Nodal Metastases Prediction in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection. Urology, 2009, 73, 850-855.	0.5	18
141	Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiotherapy and Oncology, 2013, 109, 211-216.	0.3	18
142	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World Journal of Urology, 2018, 36, 639-644.	1.2	18
143	Postoperative Orgasmic Function Increases over Time in Patients Undergoing Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2010, 7, 149-155.	0.3	17
144	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.3	17

#	Article	IF	Citations
145	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 425-438.	1.3	17
146	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. European Urology, 2021, 80, 149-159.	0.9	17
147	Bone metastases are infrequent in patients with newly diagnosed prostate cancer: Analysis of their clinical and pathologic features. Urology, 2006, 68, 362-366.	0.5	16
148	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU International, 2007, 99, 1404-1408.	1.3	16
149	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. BJU International, 2007, 100, 1249-1253.	1.3	16
150	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. European Urology, 2007, 52, 1374-1380.	0.9	16
151	Are Caucasian–European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility. Journal of Developmental and Physical Disabilities, 2012, 35, 125-132.	<b>3.</b> 6	16
152	Pelvic Lymph Node Dissection in Prostate Cancer: The Mystery Is Taking Shape. European Urology, 2013, 63, 459-461.	0.9	16
153	A novel tool to assess the risk of urinary incontinence after nerveâ€sparing radical prostatectomy. BJU International, 2013, 111, 905-913.	1.3	16
154	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e15-59.e22.	0.8	16
155	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 307.e9-307.e14.	0.8	16
156	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. European Urology Oncology, 2018, 1, 169-175.	2.6	16
157	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. BJU International, 2019, 124, 1006-1013.	1.3	16
158	Pfannenstiel versus Vertical Laparotomy in Patients Undergoing Radical Retropubic Prostatectomy with Spinal Anesthesia: Results of a Prospective, Randomized Trial. European Urology, 2005, 47, 202-208.	0.9	15
159	Is Sperm Banking of Interest to Patients With Nongerm Cell Urological Cancer Before Potentially Fertility Damaging Treatments?. Journal of Urology, 2009, 182, 1101-1107.	0.2	15
160	GENDER IS AN IMPORTANT PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PATIENT WITH TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY. Journal of Urology, 2009, 181, 635.	0.2	15
161	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology, 2019, 76, 425-429.	0.9	15
162	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2019, 17, 105-113.e2.	0.9	15

#	Article	IF	CITATIONS
163	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. Cancer Epidemiology, 2019, 58, 83-88.	0.8	15
164	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate, 2012, 72, 499-506.	1.2	14
165	Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2016, 19, 185-190.	2.0	14
166	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 528.e1-528.e5.	0.8	14
167	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. Journal of Geriatric Oncology, 2019, 10, 623-631.	0.5	14
168	Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study. BJU International, 2012, 109, 672-677.	1.3	13
169	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1497-1503.	0.8	13
170	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e17-151.e23.	0.8	13
171	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	1.0	13
172	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. Annals of Surgical Oncology, 2019, 26, 1942-1949.	0.7	13
173	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	1.2	13
174	Optimizing postoperative sexual function after radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 347-365.	0.9	12
175	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. Prostate, 2012, 72, 925-930.	1.2	12
176	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	1.6	12
177	Ejaculatory Disorders May Affect Screening for Prostate Cancer. Journal of Urology, 2007, 178, 232-238.	0.2	11
178	ORIGINAL RESEARCHâ€"SURGERY: Anatomical Radical Retropubic Prostatectomy in Patients with a Preexisting Three-Piece Inflatable Prosthesis: A Series of Case Reports. Journal of Sexual Medicine, 2009, 6, 578-583.	0.3	11
179	Sex hormoneâ€binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU International, 2011, 107, 1243-1249.	1.3	11
180	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology, 2016, 88, 97-103.	0.5	11

#	Article	IF	Citations
181	Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 775-790.	1.4	11
182	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2NO Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. European Urology Oncology, 2021, 4, 1006-1010.	2.6	11
183	Sex- and age-related differences in the distribution of bladder cancer metastases. Japanese Journal of Clinical Oncology, 2021, 51, 976-983.	0.6	11
184	Sunitinib Relieves Renal Cell Carcinoma Spinal Cord Compression. European Urology, 2007, 51, 1741-1743.	0.9	10
185	Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. International Journal of Impotence Research, 2014, 26, 201-204.	1.0	10
186	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. Clinical Genitourinary Cancer, 2016, 14, e341-e346.	0.9	10
187	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	0.8	10
188	Optimal pathological response after neoadjuvant chemotherapy for muscleâ€invasive bladder cancer: results from a global, multicentre collaboration. BJU International, 2021, 128, 607-614.	1.3	10
189	Reliability of Classification of Erectile Function Domain of the International Index of Erectile Function in Patients Affected by Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy. Urology, 2005, 66, 1140.	0.5	9
190	Lower Urinary Tract Symptoms Affect One-Third of Men in a Prostate Cancer Screening Population. Journal of Endourology, 2008, 22, 369-376.	1.1	9
191	Unsuccessful Investigation of Preoperative Sexual Health Issues in the Prostate Cancer "Coupleâ€∙ Results of a Real-Life Psychometric Survey at a Major Tertiary Academic Center. Journal of Sexual Medicine, 2009, 6, 3347-3355.	0.3	9
192	Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. International Journal of Urology, 2009, 16, 676-681.	0.5	9
193	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After RadicalACystectomy. Clinical Genitourinary Cancer, 2017, 15, e681-e688.	0.9	9
194	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. Urologia Internationalis, 2019, 102, 269-276.	0.6	9
195	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	0.9	9
196	Potency after Radical Prostatectomy: From New Techniques to Better Results. EAU-EBU Update Series, 2006, 4, 33-45.	0.7	8
197	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World Journal of Urology, 2013, 31, 267-273.	1.2	8
198	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. Urologia Internationalis, 2017, 98, 290-297.	0.6	8

#	Article	IF	CITATIONS
199	Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. European Urology, 2020, 78, 489-491.	0.9	8
200	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1344-1352.	2.3	8
201	Biopsies Performed at Tertiary Care Centers are Superior to Referral Biopsies in Predicting Pathologic Gleason Sum. Journal of Endourology, 2008, 22, 533-538.	1.1	7
202	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074.	1.6	7
203	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World Journal of Urology, 2021, 39, 1947-1953.	1.2	7
204	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 631-641.	0.8	7
205	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World Journal of Urology, 2012, 30, 533-539.	1.2	6
206	MP70-15 LONG TERM OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: RESULTS OF A SINGLE INSTITUTION SERIES WITH A MINIMUM FOLLOW-UP OF 5 YEARS. Journal of Urology, 2014, 191, .	0.2	6
207	Cell death and cell proliferation in human spina bifida. Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 106, 104-113.	1.6	6
208	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. World Journal of Urology, 2019, 37, 2707-2714.	1.2	6
209	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. European Journal of Surgical Oncology, 2019, 45, 1253-1259.	0.5	6
210	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	0.9	6
211	Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology, 2021, , .	2.6	6
212	The Evolution of Staging of Lymph Node Metastases in Clinically Localized Prostate Cancer. EAU-EBU Update Series, 2007, 5, 153-162.	0.7	5
213	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. Clinical Genitourinary Cancer, 2017, 15, e223-e228.	0.9	5
214	Converging Roads to Early Bladder Cancer. European Urology, 2020, 78, 127-130.	0.9	5
215	Rates of otherâ€cause mortality after radical cystectomy are decreasing over time—A populationâ€based analysis over two decades. Journal of Surgical Oncology, 2020, 121, 1329-1336.	0.8	5
216	Concomitant antibiotics (ATBs) use and survival outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab (PURE-01 study) Journal of Clinical Oncology, 2021, 39, 449-449.	0.8	5

#	Article	IF	CITATIONS
217	695: There is no Significant difference between on-Demand PDE5-I Vs PDE5-I As Rehabilitative Treatment in Patients Treated by Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. Journal of Urology, 2006, 175, 225-225.	0.2	5
218	639: Prediction of the Probability of Metastatic Disease after Nephrectomy for Renal Cell Carcinoma: European Validation of a Multi-Institutional Nomogram. Journal of Urology, 2007, 177, 214-214.	0.2	5
219	Emerging oral drugs for erectile dysfunction. Expert Opinion on Emerging Drugs, 2004, 9, 179-189.	1.0	4
220	DEVELOPMENT AND INTERNAL VALIDATION OF THE FIRST NOMOGRAM PREDICTING LONG-TERM PROSTATE CANCER SPECIFIC SURVIVAL IN PATIENTS WITH NODE POSITIVE PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2008, 179, 251-251.	0.2	4
221	EFFECTIVENESS OF PRE-OPERATIVE PELVIC FLOOR MUSCLE TRAINING FOR POST-PROSTATECTOMY EARLY CONTINENCE RECOVERY. Journal of Urology, 2009, 181, 591.	0.2	4
222	Prevention and Management of Postprostatectomy Erectile Dysfunction. European Urology Supplements, 2009, 8, 80-87.	0.1	4
223	Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors. Current Pharmaceutical Design, 2009, 15, 3496-3501.	0.9	4
224	Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. European Urology, 2015, 67, 71-72.	0.9	4
225	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 672.e1-672.e6.	0.8	4
226	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. European Urology Focus, 2021, 7, 1092-1099.	1.6	4
227	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 734.e11-734.e17.	0.8	4
228	Surgery and erectile dysfunction. Archivos Espanoles De Urologia, 2010, 63, 640-8.	0.1	4
229	The Case for Postoperative PDE-5 Inhibitor Drug Treatment after Radical Prostatectomy. Journal of Endourology, 2008, 22, 2025-2028.	1.1	3
230	MORTALITY PREDICTIONS IN PATIENTS WITH ADRENOCORTICAL CARCINOMA. Journal of Urology, 2009, 181, 9-10.	0.2	3
231	ACCEPTANCE OF AND DISCONTINUATION RATE FROM PAROXETINE TREATMENT IN PATIENTS WITH LIFELONG PREMATURE EJACULATION: AN OBSERVATIONAL SURVEY AT A MAJOR TERTIARY ACADEMIC CENTRE. Journal of Urology, 2009, 181, 530-530.	0.2	3
232	VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER. Journal of Urology, 2009, 181, 782-782.	0.2	3
233	Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. Translational Andrology and Urology, 2018, 7, 742-744.	0.6	3
234	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. World Journal of Urology, 2020, 38, 1229-1233.	1.2	3

#	Article	IF	CITATIONS
235	Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?. European Urology, 2021, 79, 713-716.	0.9	3
236	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Central European Journal of Urology, 2020, 73, 407-415.	0.2	3
237	Reply to Carsten Stephan et al's Letter to the Editor re: Felix KH. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction—Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. Eur Urol 2007:51:1236–43. European Urology, 2007, 51, 1448.	0.9	2
238	IS CLIMACTURIA FOLLOWING RADICAL PROSTATECTOMY ASSOCIATED WITH SURGICAL TECHNIQUE?. Journal of Urology, 2008, 179, 515-515.	0.2	2
239	Human Cytomegalovirus UL131-128 Genes Are Indispensable for Virus Growth in Endothelial Cells and Virus Transfer to Leukocytes. Journal of Virology, 2009, 83, 6323-6323.	1.5	2
240	THE USE OF LUTEINIZING HORMONE RELEASING HORMONE AGONISTS ADMINISTRATED TO PATIENTS WITH PROSTATE CANCER PREDISPOSES TO DEMENTIA: A POPULATION-BASED ANALYSIS. Journal of Urology, 2009, 181, 296-296.	0.2	2
241	A SYSTEMATIC ANALYSIS OF THE DETRIMENTAL EFFECT OF ORCHIECTOMY ON THE SKELETAL CONDITION OF MEN WITH PROSTATE CANCER. Journal of Urology, 2009, 181, 293-293.	0.2	2
242	MP51-15 TIME FROM SURGERY TO URINARY CONTINENCE SIGNIFICANTLY INFLUENCES THE SUBSEQUENT RECOVERY OF ERECTILE FUNCTION IN PATIENTS TREATED WITH BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	2
243	PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÃVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	2
244	MP58-10 PREOPERATIVE HEMOGLOBIN TO PLATELET RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY Journal of Urology, 2017, 197, .	0.2	2
245	Requiem for Open Radical Cystectomy in Bladder Cancer Patients. European Urology Oncology, 2019, 2, 196-197.	2.6	2
246	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer, 2020, 18, 35-44.e1.	0.9	2
247	380: Survival after Radical Prostatectomy and Radiotherapy: A Population-Based Study of 17 570 men. Journal of Urology, 2007, 177, 126-126.	0.2	2
248	598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy. Journal of Urology, 2007, 177, 200-200.	0.2	2
249	Final results of PEANUT: Pembrolizumab and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC) Journal of Clinical Oncology, 2020, 38, 5017-5017.	0.8	2
250	564: Clinicians Can Accurately Select Patients in Whom Lymphadenectomy may be Safely Omitted at Radical Prostatectomy. Journal of Urology, 2007, 177, 188-188.	0.2	2
251	1038: Erectile Function Following Nerve Sparing Radical Prostatectomy Correlates Well with Post -Operative Penile Length in Flaccidity and at Maximum Erection. Surgical Technique Counts. Journal of Urology, 2007, 177, 343-344.	0.2	1
252	Editorial Comment on: Outcome of Prostate Cancer Patients with Initial PSA ≥ 20 ng/ml Undergoing Radical Prostatectomy. European Urology, 2007, 52, 1065-1066.	0.9	1

#	Article	IF	CITATIONS
253	Lower urinary tract symptoms and sexual dysfunction in women. Current Sexual Health Reports, 2007, 4, 85-90.	0.4	1
254	Editorial Comment on: Current Applications for Prostate-Specific Antigen Doubling Time. European Urology, 2008, 54, 302.	0.9	1
255	ARE INFERTILE MEN LESS HEALTHY THAN FERTILE MEN? PRELIMINARY RESULTS OF A SURVEY AT A MAJOR TERTIARY ACADEMIC CENTRE. Journal of Urology, 2008, 179, 655-656.	0.2	1
256	DETECTION OF LYMPH-NODE METASTASES WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL RETROPUBIC PROSTATECTOMY: VALIDATION BY OPEN PELVIC-RETROPERITONEAL LYMPHADENECTOMY. Journal of Urology, 2009, 181, 829-829.	0.2	1
257	DISTRIBUTION OF PELVIC LYMPH NODES IS NOT SYMMETRIC. RESULTS FROM AN EXTENDED PELVIC LYMPH NODE DISSECTION SERIES. Journal of Urology, 2009, 181, 100-101.	0.2	1
258	Robot-Assisted Cystectomy: Strengths and Weaknesses. European Urology Supplements, 2011, 10, e12-e16.	0.1	1
259	771 SHOULD AN EXTENDED NODAL TEMPLATE FOR HIGH RISK PROSTATE CANCER ALWAYS INCLUDE REMOVAL OF COMMON ILIAC LYMPH NODES?. Journal of Urology, 2012, 187, .	0.2	1
260	774 HEAD-TO-HEAD COMPARISON OF LYMPH NODE DENSITY AND NUMBER OF POSITIVE LYMPH NODES IN STRATIFYING THE OUTCOME OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER SUBMITTED TO RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2013, 189,	0.2	1
261	1838 WHEN TO PERFORM LYMPH NODE DISSECTION IN RENAL CELL CARCINOMA PATIENTS: A NOVEL APPROACH TO PREOPERATIVELY ASSESS THE RISK OF LYMPH NODE INVASION AT SURGERY AND NODAL PROGRESSION DURING FOLLOW UP. Journal of Urology, 2013, 189, .	0.2	1
262	Spatial distribution of positive cores improves the selection of patients with lowâ€risk prostate cancer as candidates for active surveillance. BJU International, 2013, 112, E234-42.	1.3	1
263	Fascial Layers in Nerve Sparing Robot-Assisted Radical Prostatectomy. Urology Practice, 2014, 1, 86-91.	0.2	1
264	MP69-10 GLYCATED HEMOGLOBIN (HBA1C) LEVELS ARE INDEPENDENTLY ASSOCIATED WITH UNFAVOURABLE PROSTATE CANCER AND DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	1
265	Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41. European Urology Focus, 2021, 7, 1506-1507.	1.6	1
266	556: The Effect of Surgical Volume on the Rate of Secondary Treatment after Radical Prostatectomy. Journal of Urology, 2007, 177, 185-185.	0.2	1
267	865: Public-Awareness does not Promote Shortening of the Delay in Seeking First Medical Help for Erectile Dysfunction (ED) in the PDE5-Is ERA. Preliminary Results at Single Major Tertiary Academic Centre. Journal of Urology, 2007, 177, 288-288.	0.2	1
268	736: Erectile Function Following a Bilateral Nerve-Sparing Radical Retropubic Prostatectomy. Results of Multivariate Analysis. Journal of Urology, 2005, 173, 200-200.	0.2	1
269	The prognostic significance of capsular incision into tumor during radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 549-550.	0.7	1
270	1035: Prevalence of Erectile Dysfunction in a Prostate Cancer Screening Population. Journal of Urology, 2007, 177, 342-342.	0.2	1

#	Article	IF	CITATIONS
271	1959: A Nomogram Based Comparison of the Yield of Sextant, 12-Core, 18-Core and 21-Core Systematic Initial Biopsy. Journal of Urology, 2007, 177, 650-650.	0.2	1
272	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC) Journal of Clinical Oncology, 2018, 36, TPS4595-TPS4595.	0.8	1
273	Abstract CT003: Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase II PURE-01 study. , 2018, , .		1
274	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC) Journal of Clinical Oncology, 2019, 37, 391-391.	0.8	1
275	Sutent Relieves Renal Cell Carcinoma Spinal Cord Compression: Part II. European Urology, 2007, 52, 273-274.	0.9	0
276	Editorial Comment on: The Periprostatic Autonomic Nervesâ€"Bundle or Layer?. European Urology, 2008, 54, 1117.	0.9	0
277	NERVE-SPARING RADICAL PROSTATECTOMY DOES NOT UNDERMINE THE RATE OF BIOCHEMICAL RECURRENCE IN CAREFULLY SELECTED PATIENTS WITH PATHOLOGICALLY CONFIRMED EXTRACAPSULAR EXTENSION. Journal of Urology, 2008, 179, 646-647.	0.2	O
278	PROSTATE CANCER DETETCTION RATE AT TOTAL PSA- LEVELS BELOW 2.5ng/ml: THE UTILITY OF PERCENT FREE PSA, MEANINGFUL %fPSA CUTOFFS AND THE CLINICAL SIGNIFICANCE OF PROSTATE CANCERS DETECTED. Journal of Urology, 2008, 179, 723-723.	0.2	0
279	TIME TO CONTINENCE RECOVERY IS AN INDEPENDENT PREDICTOR OF ERECTILE FUNCTION RECOVERY AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2008, 179, 407-407.	0.2	0
280	CRITICAL ASSESSEMENT OF TOOLS TO PREDICT CLINICALLY INSIGNIFICANT PROSTATE CANCER AT RADICAL PROSTATECTOMY IN CONTEMPORARY MEN. Journal of Urology, 2008, 179, 606-606.	0.2	0
281	ASSESSMENT OF PATHOLOGICAL PROSTATE CANCER CHARACTERISTICS IN MEN WITH FAVORABLE BIOPSY FEATURES. Journal of Urology, 2008, 179, 196-196.	0.2	0
282	IS DIABETES MELLITUS ASSOCIATED WITH POORLY DIFFERENTIATED PROSTATE CANCER (PCa)?. Journal of Urology, 2008, 179, 65-65.	0.2	0
283	IS SPERM CRYOPRESERVATION BEFORE SURGICAL TREATMENT OF INTEREST IN UROLOGIC CANCER PATIENTS?. Journal of Urology, 2008, 179, 597-597.	0.2	O
284	CAN 24 CORES TRANS-RECTAL SATURATION BIOPSY IDENTIFY UNILATERAL PROSTATE CANCER POTENTIALLY AMENABLE TO FOCAL TREATMENT?. Journal of Urology, 2009, 181, 103-104.	0.2	0
285	NON-CANCER RELATED MORTALITY RATES IN EUROPEAN PATIENTS WITH T1A AND T1B RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 469-469.	0.2	0
286	ISOLATED BLADDER NECK INVOLVEMENT FROM PROSTATE CANCER SHOULD NOT BE CONSIDERED AS PT4 DISEASE. Journal of Urology, 2009, 181, 290-291.	0.2	0
287	PREDICTING ERECTILE FUNCTION RECOVERY AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY: A PROPOSAL OF A NOVEL RISK STRATIFICATION. Journal of Urology, 2009, 181, 369-370.	0.2	O
288	TIME FROM PROSTATE BIOPSY TO RADICAL PROSTATECTOMY REPRESENTS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER SIGNIFICANT UPGRADING. Journal of Urology, 2009, 181, 56-56.	0.2	0

#	Article	IF	CITATIONS
289	WHEN TO PERFORM AN INTRAFASCIAL NERVE SPARING APPROACH WITHOUT COMPROMISING CANCER CONTROL. RESULTS OF A HIGH VOLUME SINGLE SURGEON SERIES. Journal of Urology, 2009, 181, 671.	0.2	0
290	ARE IN VITRO FERTILIZATION TECHNIQUES OF INTEREST TO PATIENTS TREATED FOR GERM-CELL TESTICULAR CANCER?. Journal of Urology, 2009, 181, 730-731.	0.2	0
291	THE NUMBER OF BIOPSY CORES REPRESENTS ONE OF THE FOREMOST PREDICTOR OF CLINICALLY SIGNIFICANT GLEASON SUM UPGRADING IN LOW RISK PROSTATE CANCER PATIENTS. Journal of Urology, 2009, 181, 175-175.	0.2	0
292	PREDICTORS OF FERTILITY IN PATIENTS TREATED FOR GERM-CELL TESTICULAR CANCER. Journal of Urology, 2009, 181, 788-788.	0.2	0
293	ERECTILE FUNCTION OUTCOME OF UNTREATED PATIENTS AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 328-328.	0.2	0
294	TESTING THE MOST STRINGENT CRITERIA FOR ACTIVE SURVEILLANCE: AN ANALISIS BASED ON PATHOLOGICAL FEATURES AT RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 177-177.	0.2	0
295	PERCENTAGE OF POSITIVE CORES STRONGLY INFLUENCES THE RATE OF GLEASON SUM AGREEMENT BETWEEN PROSTATE BIOPSY AND RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 754-754.	0.2	0
296	RACE, GENDER AND REGIONAL VARIABILITY IN THE USE OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: A POPULATION-BASED ANALYSIS. Journal of Urology, 2009, 181, 499-499.	0.2	0
297	A NOVEL NOMOGRAM PREDICTING A POSITIVE [ 11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/TC) SCAN IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 781-781.	0.2	0
298	SHOULD SEPTA- AND OCTOGENARIAN PATIENTS WITH PROSTATE CANCER BE TREATED WITH RADICAL PROSTATECTOMY?. Journal of Urology, 2009, 181, 206-207.	0.2	0
299	POST-OPERATIVE ORGASMIC FUNCTION INCREASES OVER TIME IN PATIENTS SUBMITTED TO BILATERAL NERVE SPARING OPEN RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 329-329.	0.2	0
300	DEVELOPMENT AND SPLIT SAMPLE VALIDATION OF AN UPDATED NOMOGRAM PREDICTING THE PROBABILITY OF LYMPH NODE INVASION IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER UNDERGOING EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2009, 181, 757-757.	0.2	0
301	PELVIC LYMPH NODE DISSECTION SHOULD BE OMITTED IN LOW RISK PROSTATE CANCER PATIENTS. RESULTS OF A MATCHED ANALYSIS. Journal of Urology, 2009, 181, 756-757.	0.2	0
302	HOW TO SIMPLIFY PATIENT POSITIONING AND PORT PLACEMENT DURING ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (RALP). Journal of Urology, 2009, 181, 757-758.	0.2	0
303	WHICH IS THE OPTIMAL TIMING OF ERECTILE FUNCTION ASSESSMENT AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY? RESULTS FROM A PROSPECTIVE ANALYSIS. Journal of Urology, 2009, 181, 330-331.	0.2	0
304	COMPARISON BETWEEN TRANSRECTAL AND TRANSPERINEAL PROSTATE CANCER DETECTION RATE AT SATURATION BIOPSY AFTER PREVIOUS NEGATIVE BIOPSIES. RESULTS OF A TWO-INSTITUTION EXPERIENCE. Journal of Urology, 2009, 181, 709.	0.2	0
305	WHICH ARE THE PATIENTS AT RISK TO RECUR BEYOND 10 YEARS AFTER RADICAL PROSTATECTOMY?. Journal of Urology, 2009, 181, 456-457.	0.2	O
306	PARTIAL CYSTECTOMY DOES NOT UNDERMINE CANCER CONTROL IN APPROPRIATELY SELECTED PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER: A POPULATION-BASED MATCHED ANALYSIS. Journal of Urology, 2009, 181, 126-126.	0.2	0

#	Article	IF	CITATIONS
307	SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY VS. NO SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 497-497.	0.2	0
308	WHICH PATIENTS ARE AT REAL HIGH RISK FOR DYING FROM PROSTATE CANCER? A LONG-TERM FOLLOW-UP ANALYSIS ON HIGH RISK PROSTATE CANCER PATIENTS TREATED IN THE PSA ERA. Journal of Urology, 2009, 181, 270-270.	0.2	0
309	IMPACT OF STAGE MIGRATION ON THE PREVALENCE OF PELVIC LYMPH NODE METASTASES IN PATIENTS UNDERGOING EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER: A 23-YEAR SINGLE INSTITUTION EXPERIENCE. Journal of Urology, 2009, 181, 289-289.	0.2	0
310	Editorial Comment on: Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer. European Urology, 2010, 57, 639.	0.9	0
311	865 PATHOLOGICAL GLEASON SCORE DICTATES SURVIVAL IN PATIENTS WITH PT3B PCA TREATED WITH RP AND ADJUVANT RT. RESULTS FROM TWO-INSTITUTION SERIES ANALYSIS. Journal of Urology, 2010, 183, .	0.2	0
312	2120 CIRCULATING ESTRADIOL BUT NOT TESTOSTERONE IS A SIGNIFICANT PREDICTOR OF HIGH GRADE PROSTATE CANCER IN PATIENTS UNDERGOING OPEN RADICAL PROSTATECTOMY. Journal of Urology, 2010, 183, .	0.2	0
313	1801 IMPACT OF LYMPH NODE DENSITY ON CANCER-SPECIFIC SURVIVAL IN PATIENTS WITH NODE-POSITIVE RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	O
314	870 LYMPHATIC SPREAD OF NODAL METASTASES IN PROSTATE CANCER: A MAPPING SINGLE-INSTITUTION STUDY. Journal of Urology, 2010, 183, .	0.2	0
315	1244 TUMOR NECROSIS AFFECT PATIENTS SURVIVAL IN NON METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2010, 183, .	0.2	0
316	1491 IF A PRO-ERECTILE PHARMACOLOGICAL APPROACH IS CONSIDERED AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY, THIS SHOULD BE INITIATED SOON AFTER SURGERY. Journal of Urology, 2010, 183, .	0.2	0
317	1206 PRE-OPERATIVE URINARY AND ERECTILE FUNCTION REPRESENT SIGNIFICANT PREDICTORS OF POST-OPERATIVE URINARY CONTINENCE RECOVERY IN PATIENTS TREATED WITH NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2010, 183, .	0.2	0
318	652 ARE TESTICULAR PROSTHESES OF INTEREST TO PATIENTS TREATED WITH ORCHIECTOMY FOR GERM-CELL TESTICULAR CANCER?. Journal of Urology, 2010, 183, .	0.2	0
319	395 ASSESSING THE RISK OF LYMPH NODE INVASION IN PATIENTS WITH INTERMEDIATE RISK PROSTATE CANCER. A NOVEL PREDICTION TOOL. Journal of Urology, 2010, 183, .	0.2	0
320	1203 WHICH IS THE BEST DEFINITION OF ERECTILE FUNCTION RECOVERY AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY? ANALYSIS OF PATIENT SATISFACTION. Journal of Urology, 2010, 183, .	0.2	0
321	1742 OUTCOME OF PATIENTS POTENTIALLY SUITABLE FOR ACTIVE SURVEILLANCE UNDERGOING RADICAL PROSTATECTOMY AS FIRST TREATMENT CHOICE. RESULTS OF INTERMEDIATE-TERM FOLLOW-UP. Journal of Urology, 2010, 183, .	0.2	0
322	930 AGE ADJUSTED VALIDATION OF THE MOST STRINGENT CRITERIA FOR ACTIVE SURVELLIANCE: IMPLICATIONS FOR PATIENT SELECTION. Journal of Urology, 2010, 183, .	0.2	0
323	664 IMPACT OF ADJUVANT RADIOTHERAPY ON CANCER SPECIFIC SURVIVAL OF PATIENTS WITH SEMINAL VESICLE INVASION AND NODE POSITIVE DISEASE. RESULTS OF A MATCHED-ANALYSIS. Journal of Urology, 2010, 183, .	0.2	O
324	1656 IMPACT OF THE INVASION OF PERINEPHRIC OR RENAL SINUS FAT IN PATIENTS WITH RENAL CELL CARCINOMA AND VENOUS TUMOR THROMBUS. Journal of Urology, 2010, 183, .	0.2	0

#	Article	IF	CITATIONS
325	1475 INTRAFASCIAL TECHNIQUE OFFERS IMPROVED FUNCTIONAL OUTCOMES IN PATIENTS TREATED WITH BILATERAL NERVE SPARING ROBOTIC RADICAL PROSTATECTOMY. Journal of Urology, 2011, 185, .	0.2	0
326	1468 INTRAFASCIAL BILATERAL NERVE SPARING RADICAL PROSTATECTOMY: DOES THE ROBOTIC-ASSISTED APPROACH PREDISPOSE TO HIGHER RISK OF POSITIVE SURGICAL MARGINS? IMPORTANCE OF PATIENT SELECTION. Journal of Urology, 2011, 185, .	0.2	О
327	2271 RADICAL PROSTATECTOMY AFTER PREVIOUS PROSTATE SURGERY: CLINICAL AND FUNCTIONAL OUTCOMES. Journal of Urology, 2011, 185, .	0.2	O
328	841 THE VALUE OF COMPUTED TOMOGRAPHY IN DETECTING PROSTATE CANCER LYMPH NODE METASTASIS IS LIMITED EVEN IN CONTEMPORARY PATIENTS WITH VERY HIGH RISK OF NODAL INVOLVEMENT. Journal of Urology, 2011, 185, .	0.2	О
329	899 DOES BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY FOR LOCALLY ADVANCED PROSTATE CANCER INVARIABLY IMPACT CANCER-SPECIFIC MORTALITY?. Journal of Urology, 2011, 185, .	0.2	O
330	1926 PREDICTING FACTORS FOR INSIGNIFICANT CANCER AFTER A DIAGNOSIS OF ONE SINGLE MINUTE FOCUS OF PROSTATE CANCER ON NEEDLE BIOPSY. Journal of Urology, 2011, 185, .	0.2	0
331	$1628~{ m AT}$ LEAST ONE PHOSPHODIESTERASE TYPE 5 INHIBITOR DOSE PER WEEK SHOULD BE TAKEN IN ORDER TO IMPROVE ERECTILE FUNCTION RECOVERY AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, $2011,185,.$	0.2	O
332	903 CHARLSON COMORBIDITY INDEX IS NOT AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN PATIENTS WITH INTERMEDIATE AND HIGH RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY. Journal of Urology, $2011,185,.$	0.2	0
333	1637 SEMINAL VESICLE PRESERVATION DOES NOT IMPROVE FUNCTIONAL OUTCOME OF PATIENTS TREATED WITH BILATERAL NERVE SPARING RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2011, 185, .	0.2	O
334	293 LYMPH NODE DENSITY PREDICTS SURVIVAL OF PATIENTS WITH NODAL METASTASES AND PROSTATE CANCER ONLY IN PRESENCE OF MORE EXTENSIVE NODAL DISSECTION. IMPORTANCE OF ACCURATE STAGING. Journal of Urology, $2011,185,.$	0.2	0
335	1793 AGE AND AGGRESSIVE PROSTATE CANCER IN PATIENTS WITH LOW RISK CHARACTERISTICS. IMPLICATIONS FOR CONSERVATIVE MANAGEMENT. Journal of Urology, 2011, 185, .	0.2	O
336	1794 WHEN TO PERFORM BILATERAL INTRAFASCIAL NERVE-SPARING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY. IDENTIFICATION OF THE IDEAL CANDIDATE BASED ON PRE-OPERATIVE INFORMATION. Journal of Urology, 2011, 185, .	0.2	0
337	709 MORE EXTENSIVE PELVIC LYMPH NODE DISSECTION IS ASSOCIATED WITH REDUCED RISK OF CANCER PROGRESSION IN NODE NEGATIVE ORGAN CONFINED PROSTATE CANCER PATIENTS. Journal of Urology, 2011, 185, .	0.2	O
338	723 ADJUVANT RADIOTHERAPY REDUCES THE RATE OF URINARY CONTINENCE RECOVERY AFTER RADICAL PROSTATECTOMY IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER PATIENTS. Journal of Urology, 2011, 185, .	0.2	0
339	178 A SINGLE SPOT AT [(11)C]CHOLINE-PET/CT SCAN IS NOT PREDICTIVE OF A SINGLE, ISOLATED NODAL METASTASIS AT FINAL PATHOLOGY. IMPLICATIONS FOR SALVAGE TREATMENTS. Journal of Urology, 2012, 187, .	0.2	O
340	180 [11C]CHOLINE PET/CT SCAN PREDICTS SURVIVAL IN PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
341	182 EVALUATION OF LYMPH NODE RECURRENT PROSTATE CANCER WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL PROSTATECTOMY: VALIDATION BY HISTOLOGICAL ANALYSIS. Journal of Urology, 2012, 187, .	0.2	O
342	$185$ Models assessing the Need for Pelvic Lymph node dissection cannot be reliably used in Men With Prostate cancer previously treated with surgery for Benign Prostatic enlargement. Journal of Urology, 2012, $187, \ldots$	0.2	0

#	Article	IF	CITATIONS
343	$186\ \mathrm{THE}\ 2011\ \mathrm{NATIONAL}\ \mathrm{COMPREHENSIVE}\ \mathrm{CANCER}\ \mathrm{NETWORK}\ \mathrm{GUIDELINES}\ \mathrm{RECOMMENDATIONS}\ \mathrm{FOR}\ \mathrm{PELVIC}\ \mathrm{LYMPH}\ \mathrm{NODE}\ \mathrm{DISSECTION}\ \mathrm{IN}\ \mathrm{PROSTATE}\ \mathrm{CANCER}\ \mathrm{PATIENTS}\ \mathrm{ARE}\ \mathrm{NOT}\ \mathrm{ACCURATE}.\ \mathrm{A}\ \mathrm{PLEA}\ \mathrm{FOR}\ \mathrm{RENEWAL}.$ Journal of Urology, 2012, 187, .	0.2	O
344	187 IS [11C]CHOLINE PET/CT RECOMMENDED FOR RESTAGING PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY WHEN PSA IS LOWER THAN 1 NG/ML?. Journal of Urology, 2012, 187, .	0.2	0
345	365 IDENTIFYING PATIENTS AT REAL RISK OF DYING FROM PROSTATE CANCER. A NOVEL RISK SCORE FOR THE SELECTION OF CANDIDATES FOR ADJUVANT RADIATION THERAPY. Journal of Urology, 2012, 187, .	0.2	O
346	768 DO NODAL METASTASES INVARIABLY IMPACT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER? IMPORTANCE OF LOCAL DISEASE STATUS. Journal of Urology, 2012, 187, .	0.2	0
347	770 A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS. Journal of Urology, 2012, 187, .	0.2	O
348	772 PREDICTORS OF LONG-TERM SURVIVAL OF PATIENTS WITH HIGH VOLUME OF NODAL METASTASES AT EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER. THE IMPORTANCE OF AN INTEGRATED, MULTIMODAL APPROACH. Journal of Urology, 2012, 187, .	0.2	0
349	2233 AN INITIAL SERUM PSA LEVEL LESS THAN 5 NG/ML AT DIAGNOSIS DOES NOT CORRELATE WITH TUMOR VOLUME IN LOW RISK PROSTATE CANCER PATIENTS. IMPLICATIONS FOR CONSERVATIVE TREATMENTS. Journal of Urology, 2012, 187, .	0.2	0
350	1125 A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
351	2204 HOW TO EXPAND INDICATIONS FOR ACTIVE SURVEILLANCE WITHOUT COMPROMISING CANCER CONTROL. THE IMPORTANCE OF THE EXTENT OF BIOPSY SAMPLING. Journal of Urology, 2012, 187, .	0.2	О
352	1126 THE EFFECT OF PREOPERATIVE CANCER AGGRESSIVENESS ON LEARNING CURVE AMONG HIGH VOLUME SURGEONS PERFORMING RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.2	0
353	1379 THE KEY ROLE OF TIME IN PREDICTING POST-RADICAL PROSTATECTOMY ERECTILE FUNCTION RECOVERY: CONDITIONAL SURVIVAL ANALYSES. Journal of Urology, 2012, 187, .	0.2	O
354	2066 MISCLASSIFICATION OF MICRO-FOCUS PROSTATE CANCER DECREASES WITH THE EXTENT OF BIOPSY SAMPLING. IMPORTANCE OF ACCURATE DETECTION. Journal of Urology, 2012, 187, .	0.2	0
355	2111 SERUM SEX STEROIDS DEPICT A NON LINEAR U-SHAPED ASSOCIATION WITH HIGH RISK PROSTATE CANCER AT RADICAL PROSTATECTOMY - IMPLICATIONS FOR INDIVIDUALIZED HORMONAL THERAPY. Journal of Urology, 2012, 187, .	0.2	0
356	372 THE NUMBER OF POSITIVE NODES IS THE STRONGEST PREDICTOR OF CANCER SPECIFIC SURVIVAL IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR PATHOLOGICAL T3 PROSTATE CANCER. Journal of Urology, 2013, 189, .	0.2	0
357	2235 THE NUMBER OF BIOPSY CORES TAKEN IS A MAJOR PREDICTOR OF UNFAVORABLE PROSTATE CANCER AT FINAL PATHOLOGY IN PATIENTS CANDIDATE FOR ACTIVE SURVEILLANCE: CLINICAL IMPLICATIONS. Journal of Urology, 2013, 189, .	0.2	0
358	743 CONCORDANCE BETWEEN CLINICAL AND PATHOLOGICAL LYMPH NODE INVASION IN RENAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.2	0
359	340 LONG TERM DIABETES MELLITUS INCREASES THE RISK OF POORLY DIFFERENTIATED TUMOR IN PROSTATE CANCER PATIENTS. Journal of Urology, 2013, 189, .	0.2	O
360	345 CHANGING AND UNCHANGING FACE OF HIGH RISK PROSTATE CANCER. RESULTS FROM A 15-YEAR, SINGLE INSTITUTION SERIES. Journal of Urology, 2013, 189, .	0.2	0

#	Article	IF	CITATIONS
361	247 SPATIAL DISTRIBUTION OF POSITIVE CORES DECREASES MISCLASSIFICATION RATES OF PATIENTS WITH LOW RISK PROSTATE CANCER CANDIDATE FOR ACTIVE SURVEILLANCE. Journal of Urology, 2013, 189, .	0.2	0
362	MP37-20 INDIVIDUAL SURGEON COMMITMENT TO PELVIC LYMPH NODE DISSECTION RATHER THAN SURGICAL VOLUME IS A MAJOR DETERMINANT OF THE EXTENT OF NODAL DISSECTION DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
363	PD15-09 PELVIC LYMPH NODE DISSECTION CAN BE SAFELY OMITTED IN MEN WITH A RISK OF NODAL METASTASES â‰奪% BASED ON THE BRIGANTI NOMOGRAM: VALIDATION OF THE EAU GUIDELINS RECCOMENDATIONS FOR NODAL DISSECTION BASED ON PATIENT OUTCOME. Journal of Urology, 2014, 191,	0.2	O
364	PD15-07 ASSESSING THE OPTIMAL EXTENT OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH SINGLE PELVIC NODAL UPTAKE AT [11C]-CHOLINE PET/CT SCAN FROM RECURRING PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	O
365	PD15-12 HYPOGONADISM IS AN INDEPENDENT PREDICTOR OF NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING EXTENDED PELVIC LYMPH NODE DISSECTION. Journal of Urology, 2014, 191, .	0.2	0
366	MP46-05 IMPACT OF MINIMALLY INVASIVE APPROACH ON THE PROBABILITY OF EARLY COMPLETE FUNCTIONAL RECOVERY AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.2	0
367	MP37-09 MORE EXTENSIVE PELVIC LYMPH NODE DISSECTIONS DURING ROBOTIC ASSISTED RADICAL PROSTATECTOMY ARE ASSOCIATED WITH HIGHER RATES OF PERI-OPERATIVE COMPLICATIONS. RESULTS OF A SINGLE INSTITUTION SERIES. Journal of Urology, 2014, 191, .	0.2	O
368	MP69-18 HOW TO EXPAND INDICATIONS FOR ACTIVE SURVEILLANCE WITHOUT COMPROMISING CANCER CONTROL: A SYSTEMATIC ASSESSMENT OF THE CURRENTLY USED CRITERIA FOR PROSTATE CANCER PATIENTS. Journal of Urology, 2014, 191, .	0.2	0
369	MP70-21 ASSESSING THE OPTIMAL POST-OPERATIVE MANAGEMENT OF NODE POSITIVE PROSTATE CANCER PATIENTS:RESULTS FROM MULTI-INSTITUTIONAL SERIES. Journal of Urology, 2014, 191, .	0.2	O
370	MP26-18 MULTI-ISTITUTIONAL CONTROLLED STUDIES DO NO REFLECT THE PATIENT'S COMPLIANCE TO BCG ENCOUNTERED IN CLINICAL PRACTICE. RESULTS ON 411 PATIENTS. Journal of Urology, 2015, 193, .	0.2	0
371	MP83-17 IMPACT OF INTRA-OPERATIVE TRANSFUSION ON SURVIVAL OF PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	O
372	MP63-04 CLINICAL AND PATHOLOGICAL LYMPH NODE PROGRESSION IN PATIENTS WITH A CT1-T2 NO MO RENAL MASS: SHALL WE FOREVER DISCARD THE USE OF LYMPH NODE DISSECTION IN LOW RISK PATIENTS?. Journal of Urology, 2015, 193, .	0.2	0
373	PD32-09 VERY LONG-TERM ONCOLOGICAL OUTCOMES OF PATIENTS TREATED WITH RADICAL PROSTATECTOMY FOR NODE POSITIVE PROSTATE CANCER: A MULTI-INSTITUTIONAL, CONDITIONAL SURVIVAL ANALYSIS. Journal of Urology, 2015, 193, .	0.2	O
374	PD30-06 ASSESSING THE ROLE OF TIME FROM PROSTATE CANCER DIAGNOSIS TO RADICAL PROSTATECTOMY: CAN SURGERY BE POSTPONED SAFELY?. Journal of Urology, 2016, 195, .	0.2	0
375	PD33-02 VARIANT HISTOLOGIC DIFFERENTIATION IN BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: INCIDENCE AND LONG TERM SURVIVAL IN A SINGLE INSTITUTION STUDY Journal of Urology, 2016, 195, .	0.2	O
376	MP63-11 PREOPERATIVE PLATELET TO LYMPHOCYTE RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY DUE TO BLADDER CANCER. Journal of Urology, 2016, 195, .	0.2	0
377	PD33-10 THE PRESENCE OF RESIDUAL CARCINOMA IN SITU ALONE (PTIS) IN PATIENTS TREATED WITH RADICAL CYSTECTOMY DOES NOT AFFECT LONG TERM RECURRENCE AND SURVIVAL RATES. Journal of Urology, 2016, 195, .	0.2	O
378	PD39-04 TIMING OF BLOOD TRANSFUSION AND NOT ABO BLOOD TYPE IS ASSOCIATED WITH SURVIVAL IN PATIENTS TREATED WITH RADICAL CYSTECTOMY FOR NON-METASTATIC BLADDER CANCER: RESULTS FROM A SINGLE HIGH-VOLUME INSTITUTION. Journal of Urology, 2016, 195, .	0.2	О

#	Article	IF	CITATIONS
379	MP09-05 DOES THE NEW PROSTATE CANCER GRADING SYSTEM IMPROVE PREDICTION OF CLINICAL RECURRENCE?. Journal of Urology, 2016, 195, .	0.2	O
380	MP58-13 IS TRANSURETHRAL RESECTION ALONE ENOUGH FOR DIAGNOSIS HISTOLOGICAL VARIANTS? A SINGLE CENTER STUDY. Journal of Urology, 2017, 197, .	0.2	0
381	MP54-19 IMPACT OF PROSTATE INVOLVEMENT ON OUTCOMES INÂPATIENTS TREATED WITH RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER. Journal of Urology, 2017, 197, .	0.2	O
382	PD15-08 ASSOCIATION BETWEEN EARLY URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: DEVELOPMENT OF A NOVEL POSTOPERATIVE RISK SCORE TO OPTIMIZE PATIENT COUNSELING AND FOLLOW-UP. Journal of Urology, 2017, 197, .	0.2	О
383	MP58-11 IMPACT OF INTRA- AND POST-OPERATIVE BLOOD TRANSFUSION ON THE INCIDENCE, TIMING AND PATTERN OF DISEASE RECURRENCE AFTER RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	O
384	MP97-12 CHANGES OVER TIME IN NODE POSITIVE PROSTATE CANCER RATES AND FEATURES AMONG MEN TREATED WITH RADICAL PROSTATECTOMY AND EXTENTED PELVIC LYMPH NODE DISSECTION AT A SINGLE REFERRAL CENTER. Journal of Urology, 2017, 197, .	0.2	0
385	MP54-15 PURE BUT NOT MIXED HISTOLOGICAL VARIANTS ARE ASSOCIATED WITH POOR SURVIVAL AT RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS. Journal of Urology, 2017, 197, .	0.2	O
386	MP58-01 INCOMPLETENESS OF THE TRANSURETHRAL RESECTION AS A PREDICTOR OF ADVERSE PATHOLOGICAL FEATURES AT THE TIME OF RADICAL CYSTECTOMY: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY SELECTION. Journal of Urology, 2017, 197, .	0.2	0
387	MP58-09 PREDICTING LOCAL FAILURE AFTER RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS: IMPLICATIONS FOR THE SELECTION OF CANDIDATES AT ADJUVANT RADIATION THERAPY. Journal of Urology, 2017, 197, .	0.2	O
388	Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12–9. European Urology Oncology, 2021, 4, 126.	2.6	0
389	Re: Paolo Dell'Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery. Eur Urol Focus 2021;7:352–8. European Urology Focus, 2022, 8, 890.	1.6	O
390	Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion. Société Internationale D'urologie Journal, 2021, , 282-298.	0.2	0
391	390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy. Journal of Urology, 2007, 177, 130-130.	0.2	O
392	466: Age is an Independent Predictor of Bone Metastasis at Prostate Cancer Diagnosis. Journal of Urology, 2007, 177, 156-156.	0.2	0
393	1147: Favorable Long-Term Outcomes in Patients with Seminal Vesicle Invasion or Lymph Node Invasion at Radical Prostatectomy. Journal of Urology, 2007, 177, 378-379.	0.2	O
394	569: Differences in Clinical and Pathological Characteristics of Patients Diagnosed with Clinically Localized Prostate Cancer, Subjected to Either Open or Robotic-Assisted Radical Prostatectomy. Journal of Urology, 2007, 177, 190-190.	0.2	0
395	1888: Digital Rectal Examination is an Independent Predictor of Pathologic Gleason 7-10 in Patients Diagnosed with Extended Biopsy Schemes and Treated with Radical Prostatectomy. Journal of Urology, 2007, 177, 627-628.	0.2	O
396	859: Ejaculatory Dysfunction Affects One in Two Men Undergoing Screening for Prostate Cancer. Journal of Urology, 2007, 177, 286-286.	0.2	0

#	Article	IF	Citations
397	232: Natural History of Treated Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2007, 177, 77-78.	0.2	0
398	727: Early Recurrences after Radical Prostatectomy for Prostate Cancer: Can we Identify Those Patients?. Journal of Urology, 2007, 177, 244-244.	0.2	0
399	1495: Stress Urinary Incontinence and Erectile Dsyfunction in a Prostate Cancer Screening Cohort. Journal of Urology, 2007, 177, 493-493.	0.2	0
400	1713: Accuracy of Percent Free Psato Predict Prostate Cancer at Biopsy in PSA Ranges Lower than 2.5ng/ml. Journal of Urology, 2007, 177, 569-570.	0.2	0
401	1023: The Role of Digital Rectal Examination in Prediction of Pathological Stage After Radical Prostatectomy in Contemporary Patients. Journal of Urology, 2007, 177, 337-338.	0.2	0
402	329: When to Perform a Bone Scan in Patients with Prostate Cancer. A novel Nomogram. Journal of Urology, 2007, 177, 111-112.	0.2	0
403	1879: Larger Prostate Glands are Associated with a Lower Rate of Upgrading between Biopsy and Radical Prostatectomy. Journal of Urology, 2007, 177, 624-624.	0.2	0
404	845: Extended Biopsy Schemes are Associated with Similar Pathological Characteristics but Lower Biochemical Recurrence than Sextant Biopsy. Journal of Urology, 2007, 177, 282-282.	0.2	0
405	1964: Digital Rectal Examination is an Independent Predictor of Prostate Cancer at Initial Biopsy in Contemporary Men Exposed to Extended Core Biopsy. Journal of Urology, 2007, 177, 652-652.	0.2	0
406	1143: Positive Surgical Margins Increase the Risk of Biochemical Recurrence Independently from Pathological Stage or Grade. Journal of Urology, 2007, 177, 377-377.	0.2	0
407	724: Excellent Long-Term Outcome of Patients with Low Volume of Lymph Node Invasion Treated with Extended Pelvic Lymph Node Dissection at the time of Radical Prostatectomy. Journal of Urology, 2007, 177, 243-243.	0.2	0
408	1892: Body Mass Index does not Alter Prostate-Specific Antigen or Percent Free Prostate-Specific Antigen in Men Undergoing Prostate Cancer Screening. Journal of Urology, 2007, 177, 628-629.	0.2	0
409	729: A Risk Adjusted Follow Up Scheme after Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2007, 177, 245-245.	0.2	0
410	321: No Differences in Biochemical Recurrence between NO and NX Patients Subjected to Radical Prostatectomy: A Matched Analyses on 5977 Patients. Journal of Urology, 2007, 177, 108-109.	0.2	0
411	1031: Comparison of Stage Migration Patterns Between North America and Europe: An Analysis of 11350 Men. Journal of Urology, 2007, 177, 341-341.	0.2	0
412	565: 30-Day Mortality after Radical Prostatectomy in Over 9000 Patients: Validation of a Predictive Nomogram. Journal of Urology, 2007, 177, 188-189.	0.2	0
413	1714: Percentage of Free PSA is the Most Informative Predictor of the Risk of Prostate Cancer on Initial Biopsy Across all Ages. Journal of Urology, 2007, 177, 570-570.	0.2	0
414	465: Proposal for a Correction of the AJCC Staging System for Prostate Cancer Patients Treated with Radical Prostatectomy. Journal of Urology, 2007, 177, 156-156.	0.2	0

#	ARTICLE	IF	CITATIONS
415	1949: A Comparison between the Prevalence of Prostate Cancer on Needle Biopsy between Referral and PCPT Placebo ARM in Men with PSA Values 0-4 NG/ML. Journal of Urology, 2007, 177, 647-647.	0.2	0
416	The Utility of PDE5 Inhibitors After Radical Prostatectomy., 2009,, 177-196.		0
417	Penile Rehabilitation After Robotic Radical Prostatectomy: The Best Strategy. , 2011, , 361-370.		O
418	Mid-term complications after placement of the male adjustable suburethral sling: a single center experience. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2011, 37, 552-553.	0.7	0
419	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets Journal of Clinical Oncology, 2019, 37, 4535-4535.	0.8	0
420	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC) Journal of Clinical Oncology, 2019, 37, 4540-4540.	0.8	0
421	Dissecting outcomes of patients (pts) with <ppt2n0 (mibc):="" (nac)="" 2020,="" 38,="" 5043-5043.<="" a="" after="" bladder="" cancer="" chemotherapy="" clinical="" collaboration="" disease="" for="" from="" international,="" invasive="" journal="" large,="" multicenter="" muscle="" neoadjuvant="" of="" oncology,="" results="" td=""><td>0.8</td><td>O</td></ppt2n0>	0.8	O
422	Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2020, 38, 533-533.	0.8	0
423	Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pTO) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC) Journal of Clinical Oncology, 2020, 38, 539-539.	0.8	O
424	Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal of Urology, 2020, 203, 624-624.	0.2	0